Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 4/20 | 0.49 |
| ▸ | CDK2 | P24941 | 4/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.49 |
| ▸ | CA9 | Q16790 | 10/20 | 0.47 |
| ▸ | CA1 | P00915 | 8/20 | 0.47 |
| ▸ | CA2 | P00918 | 8/20 | 0.47 |
| ▸ | CA4 | P22748 | 6/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5371941 | 0.88 | CA9 (0.50) | CCNA2CDK2CCNA1CA9CA1 | |
| SCHEMBL5254020 | 0.82 | CCNA2 (0.50) | CCNA2CDK2CCNA1CA9CA1 | |
| SCHEMBL6792114 | 0.82 | CCNA2 (0.50) | CCNA2CDK2CCNA1CA9CA1 | |
| SCHEMBL5335768 | 0.80 | IKBKB (0.57) | CCNA2CDK2CCNA1IKBKB | |
| SCHEMBL6352140 | 0.80 | RAD52 (0.56) | CCNA2CDK2CCNA1CA9CA1 | |
| Hydrochloric Acid SCHEMBL6800512 | 0.79 | PTGS2 (0.51) | CCNA2CDK2CCNA1CA9CA1 | |
| SCHEMBL6660718 | 0.78 | CA9 (0.55) | CCNA2CDK2CCNA1CA9CA1 | |
| SCHEMBL5228990 | 0.77 | CCNA2 (0.79) | CCNA2CDK2CCNA1IKBKB | |
| SCHEMBL4154814 | 0.76 | CA9 (0.54) | CCNA2CDK2CCNA1CA9CA1 | |
| SCHEMBL5339056 | 0.76 | IKBKB (0.54) | CCNA2CDK2CCNA1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | CCNA2 270/4885CDK2 29/4885CCNA1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.